Capital Research Global Investors 13D and 13G filings for Alnylam Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-14 10:19 am Purchase | 2026-03-31 | 13G | ALYNLAM PHARMACEUTICALS INC ALNY | Capital Research Global Investors | 9,471,181 7.100% | 2,502,668 (+35.91%) | Filing |
| 2025-02-13 2:14 pm Purchase | 2024-12-31 | 13G | ALYNLAM PHARMACEUTICALS INC ALNY | Capital Research Global Investors | 6,968,513 5.400% | 6,968,513 (New Position) | Filing |